Inhibitors of SARS-CoV-2 main protease: Biological efficacy and toxicity aspects

The emergence of the highly contagious respiratory disease, COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a significant global public health concern. To combat this virus, researchers have focused on developing antiviral strategies that target speci...

Full description

Saved in:
Bibliographic Details
Published in:Toxicology in vitro 2023-10, Vol.92, p.105640-105640, Article 105640
Main Authors: Viskupicova, Jana, Rezbarikova, Petronela, Kovacikova, Lucia, Kandarova, Helena, Majekova, Magdalena
Format: Article
Language:English
Subjects:
ADMET
Anti-inflammatory
Antibacterial
COVID-19
Mpro inhibitors
Specific
toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The emergence of the highly contagious respiratory disease, COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a significant global public health concern. To combat this virus, researchers have focused on developing antiviral strategies that target specific viral components, such as the main protease (Mpro), which plays a crucial role in SARS-CoV-2 replication. While many compounds have been identified as potent inhibitors of Mpro, only a few have been translated into clinical use due to the potential risk-benefit trade-offs. Development of systemic inflammatory response and bacterial co-infection in patients belong to severe, frequent complications of COVID-19. In this context, we analysed available data on the anti-inflammatory and antibacterial activities of the SARS-CoV-2 Mpro inhibitors for possible implementation in the treatment of complicated and long COVID-19 cases. Synthetic feasibility and ADME properties were calculated and included for better characterisation of the compounds' predicted toxicity. Analysis of the collected data resulted in several clusters pointing to the most prospective compounds for further study and design. The complete tables with collected data are attached in Supplementary material for use by other researchers. •Inflammatory response and bacterial co-infection enlarge complications course of COVID-19•Side effects of drugs may worsen COVID-19 treatment•Specific toxicities are key properties for drug candidates•Analysis of compiled data may pointed out prospective compounds•Low-toxic inhibitors with antibacterial and anti-inflammatory effects identified
ISSN:0887-2333
1879-3177
DOI:10.1016/j.tiv.2023.105640